» Articles » PMID: 10760760

Adenocarcinoma of the Lung in Young Patients: the M. D. Anderson Experience

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2000 Apr 13
PMID 10760760
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Surveillance, Epidemiology, and End Results (SEER) data for the years 1973-1992 documented that patients age < 50 years presented with more advanced disease. Because of the increase in the incidence rate of lung adenocarcinoma in the past few decades and the presentation of more advanced disease in young patients, this study was performed to determine whether differences in survival exist between younger and older patients with this disease.

Methods: The authors reviewed the experience of the University of Texas M. D. Anderson Cancer Center between 1985-1994, encompassing 157 patients age < 40 years of 4097 patients registered with adenocarcinoma of the lung. For comparison, 157 patients age > 50 years with lung adenocarcinoma were selected; these patients were matched for gender, stage of disease at presentation, and definitive therapy modality to assess survival differences more accurately. Data regarding exposure to second-hand smoke were not collected secondary to lack of documentation in the charts reviewed.

Results: There were no significant differences between the 2 groups with regard to the overall survival rate (P = 0.34) or time to progression (P = 0.43). Smoking status (current vs. former vs. never-smoker) was not found to be predictive of survival in either the younger group (P = 0.51) or the older group (P = 0.92).

Conclusions: The data from the current study indicate that overall survival and disease free survival rates were not significantly different in these two groups. Thus, the younger patient population should be treated similarly to the older patient population. However, a surprisingly high percentage of younger patients were female (45%) and had never smoked (27%), suggesting that risk factors other than active smoking may be involved in lung carcinogenesis in these patients.

Citing Articles

Suicide Mortality Risk among Patients with Lung Cancer-A Systematic Review and Meta-Analysis.

Hofmann L, Heinrich M, Baurecht H, Langguth B, Kreuzer P, Knuttel H Int J Environ Res Public Health. 2023; 20(5).

PMID: 36901154 PMC: 10002176. DOI: 10.3390/ijerph20054146.


Expression of miRNA-25 in young and old lung adenocarcinoma.

Boldrini L, Giordano M, Melfi F, Lucchi M, Fontanini G J Res Med Sci. 2022; 26:132.

PMID: 35126595 PMC: 8772505. DOI: 10.4103/jrms.JRMS_830_19.


Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Megaro G, Miele E, Spinelli G, Alessi I, Del Baldo G, Cozza R Cancer Rep (Hoboken). 2022; 5(3):e1483.

PMID: 35092185 PMC: 8955048. DOI: 10.1002/cnr2.1483.


Case Report: Primary Bilateral Minimally Invasive Adenocarcinoma of the Lungs in an 11-Year-Old Child: A Rare Case.

Lei X, Zheng Y, Zhang G, Zheng H Front Surg. 2021; 8:741744.

PMID: 34765637 PMC: 8575692. DOI: 10.3389/fsurg.2021.741744.


Younger, not better: No influence of age on lung cancer stage at diagnosis in South Africa.

Calligaro G Afr J Thorac Crit Care Med. 2021; 26(2).

PMID: 34240025 PMC: 8203079. DOI: 10.7196/AJTCCM.2020.v26i2.075.